Combined high-dose and high-LET exposure around breast implants was associated with severe capsular contracture after proton postmastectomy radiotherapy.
Multi-RBE carbon-ion optimization increased near-minimum GTV LET by 29.2% while maintaining conventional dose coverage and interfraction robustness.
A DAHANCA 35 patient decision aid was feasible and acceptable, but its value depended strongly on clinician introduction and engagement.
Twelve VMAT lattice courses produced 65% median tumor shrinkage and no local progression during short follow-up in bulky hepatocellular carcinoma.
In eight bulky tumor sites, flattening-filter VMAT lattice radiotherapy produced 75% symptom relief with no grade 3 or higher acute toxicity.
A longitudinal CT radiomics model identified post-SBRT rib fracture risk with 85% sensitivity and 71% specificity in validation.
Several cannabinoids reduced therapy-induced glioblastoma apoptosis and enhanced clonogenic survival in vitro, raising concern about concurrent use during treatment.
Low CAVIN3 expression was associated with higher treatment response and substantially longer progression-free survival after radiotherapy for cervical cancer.
Regional brain dose showed no significant association with cognition through 12 months, although only 24 patients completed one-year testing.
Tumor location, hypertension and albumin predicted moderate-to-severe acute esophagitis with an internally validated AUC of 0.816.
Both dose rates increased mitochondrial respiration after irradiation, with no clear FLASH-specific mitochondrial phenotype under normoxic conditions.
Bullous pemphigoid emerged after seven radiotherapy fractions during pembrolizumab, spreading beyond the treatment field and ultimately preventing completion of both therapies.
Ultra-high dose-rate protons produced fewer DNA breaks at low scavenger concentration, but the effect diminished or reversed under other experimental conditions.
Baseline miR-144-5p and miR-222-3p differed in patients who later developed greater radiation toxicity, but the signals require validation.
An iridium-192 boost increased median progression-free survival from 8.6 to 11.2 months, without a significant overall-survival improvement.